Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Birth and death records registered at sea, Judicial death declarations, Records related to soldiers and sailors under certain special circumstances, Divorce judgments or rulings, when the marriage was celebrated in a territory occupied by the enemy.
Environmental cues that influence the release of gametes into the water vary from species to species. The cues involve temperature change, lunar cycle, day length, and possibly chemical signalling. Other factors that affect the rhythmicity of organisms in marine habitats include salinity, mechanical forces, and pressure or magnetic field changes. Mass coral spawning often occurs at night on days following a full moon. A full moon is equivalent to four to six hours of continuous dim light exposure, which can cause light-dependent reactions in protein. Corals contain light-sensitive cryptochromes, proteins whose light-absorbing flavin structures are sensitive to different types of light. This allows corals such as Dipsastraea speciosa to detect and respond to changes in sunlight and moonlight. Moonlight itself may actually suppress coral spawning. The most immediate cue to cause spawning appears to be the dark portion of the night between sunset and moonrise. Over the lunar cycle, moonrise shifts progressively later, occurring after sunset on the day of the full moon. The resulting dark period between day-light and night-light removes the suppressive effect of moonlight and enables coral to spawn. The spawning event can be visually dramatic, clouding the usually clear water with gametes. Once released, gametes fertilize at the water's surface and form a microscopic larva called a planula, typically pink and elliptical in shape. A typical coral colony needs to release several thousand larvae per year to overcome the odds against formation of a new colony.
=== Bridge and culvert design === Stream power can be used as an indicator of potential damages to bridges as a result of large rain events and how strong bridges should be designed in order to avoid damage during these events. Stream power can also be used to guide culvert and bridge design in order to maintain healthy stream morphology in which fish are able to continuing traversing the water course and no erosion processes are initiated.
== Research == A wave of enthusiasm for secretin as a possible treatment for autism arose in the 1990s based on a hypothetical gut-brain connection; as a result the NIH ran a series of clinical trials that showed that secretin was not effective, which brought an end to popular interest. A high-affinity and optimized secretin receptor antagonist (Y10,c[E16,K20],I17,Cha22,R25)sec(6-27) has been designed and developed which has allowed the structural characterization of secreting inactive conformation.
Sources: en.wikipedia.org
==== Polysome profiling ==== Polysome profiling is a technique used to characterize the degree of translation of one or more mRNAs. A highly translated mRNA exists as a polysome, meaning it is complexed with multiple ribosomes. mRNAs translated at lower levels are complexed with fewer ribosomes. In polysome profiling, a sucrose gradient is used to separate molecular complexes in a cell lysate based on size. The fractions from the column are analyzed by sequencing or other methods. The translation rate of mRNAs is determined based on their detection and abundance in the fractions of lower and higher molecular weight.
During the dot-com boom, Webvan, an online-only supermarket, was formed and went bankrupt after three years and was acquired by Amazon. The British online supermarket Ocado, which uses a high degree of automation in its warehouses, was the first successful online-only supermarket. Ocado expanded into providing services to other supermarket firms such as Waitrose and Morrisons. Grocery stores such as Walmart employ food delivery services offered by third parties such as DoorDash. Other online food delivery services, such as Deliveroo in the United Kingdom, have begun to pay specific attention to supermarket delivery. Delivery robots are offered by various companies partnering with supermarkets. Micro-fulfillment centers (MFC) are relatively small warehouses with sophisticated automated rack-and-tote systems which prepare orders for pickup and delivery. Once the order is complete, the customer will pick it up (i.e. "click-and-collect") or have it fulfilled via home delivery. Supermarkets are investing in micro-fulfillment centers with the hope that automation can help reduce the costs of online commerce and e-commerce by shortening the distances from store to home and speeding up deliveries. MFCs are said by many to be the key to profitably fulfilling online orders.
During the fermentation process, optimal time of fermentation, temperature, oxygen, humidity, and pH levels are required to encourage the growth of the Rhizopus mold, while discouraging the growth of undesired microorganisms. The pH level should be kept around 3 -5 by adding a mild acidulant such as vinegar, lactic acid, or acetic acid, thereby favoring mold growth and restricting the growth of spoilage microorganisms. Oxygen is required for Rhizopus spp. growth, but should be maintained at low levels to prevent the production of undesired microorganisms. Under conditions of lower temperature, or higher ventilation, gray or black patches of spores may form on the surface—this is not harmful, and should not affect the flavor or quality of the tempeh. This sporulation is normal on fully mature tempeh. A mild ammonia smell may accompany good tempeh as it ferments, but it should not be overpowering. Traditional tempeh is often produced in Indonesia using Hibiscus tiliaceus leaves. The undersides of the leaves are covered in downy hairs (known technically as trichomes) to which the mold Rhizopus oligosporus can be found adhering in the wild. Soybeans are pressed into the leaf, and stored. Fermentation occurs resulting in tempeh. In particular, the tempeh undergoes salt-free aerobic fermentation. Tempeh made with traditional inoculation methods are also more likely to include molds of other species including Rhizopus arrhizus and Rhizopus delemar which may outcompete Rhizopus oligosporus as the dominant mold.
Sources: en.wikipedia.org
The climate of the islands is oceanic, with moderate and fairly uniform temperatures and heavy rainfall. Fogs are almost constant. Summer weather is much cooler than Southeast Alaska (around Sitka), but the winter temperature of the islands and of the Alaska Panhandle is nearly the same. According to the Köppen climate classification system, the area southwest of 53.5°N 167.0°W / 53.5; -167.0, on Unalaska Island, has a "Subpolar Oceanic Climate" (type "Cfc", as does Reykjavík, Tórshavn, Punta Arenas, Ushuaia and the Auckland Islands), characterized by the coldest month averaging above 0 °C (32 °F), one to three months averaging above 10 °C (50 °F), and no significant precipitation differences between seasons. To the northeast of that point, the climate becomes "Subarctic With Cool Summers And Year Around Rainfall" (type "Dfc", like Petropavlovsk-Kamchatsky, Murmansk, St. Moritz, and Labrador City), where it is similar albeit colder, with the coldest month averaging below 0 °C (32 °F). During the winter, the islands become the center of a semi-permanent low-pressure area called the Aleutian Low. The mean annual temperature for Unalaska, the most populated island of the group, is about 38 °F (3 °C), being about 30 °F (−1 °C) in January and about 52 °F (11 °C) in August. The highest and lowest temperatures recorded on the islands were 78 °F (26 °C) and 5 °F (−15 °C), respectively. The average amount of annual rainfall is about 80 inches (2,000 mm); Unalaska, with about 250 rainy days per year, is said to be one of the rainiest places within the U.S.
In 2003 Håkan Steiner and coworkers and Roman Dziarski and coworkers discovered that mouse and human PGLYRP2 (PGRP-L) proteins encoded by the mouse and human PGLYRP2 genes are N-acetylmuramoyl-L-alanine amidases. Recombinant and native human PGLYRP2 proteins were then further shown to be identical with the previously identified and purified serum NAMLAA.
Gay-Lussac's law A chemical law used for each of the two relationships derived by French chemist Joseph Louis Gay-Lussac and which concern the properties of gases, though the name is more usually applied to his law of combining volumes.
== PIDD1 and Cancer == Tumor protein p53 (TP53, often referred to as p53) regulates a sophisticated network of tumor-suppressive responses to prevent the growth and persistence of cells with extra centrosomes. These responses include halting cell division, promoting cellular senescence, initiating controlled cell death, and, in instances of whole-genome duplication, activating immune surveillance by cytotoxic T cells. CASP2 plays a very important role in regulation and activation of p53 in response to extra centrosomes. Its activation is dependent on the formation of the "PIDDosome," a large protein complex that includes p53-induced death domain protein 1 (PIDD1), CASP2, and [RIPK1]] containing a death domain (CRADD, commonly referred to as RAIDD). This complex enables CASP2 to inactivate MDM2, a key inhibitor of p53, thereby promoting the activation of p53. In a study, Evans and colleagues conducted a genome-wide CRISPR-Cas9 knockout screen using immortalized retinal pigment epithelial cells (hTERT RPE-1), modified to overexpress PLK4, which induces centriole overduplication. The cells also had constant depletion of ubiquitin-specific peptidase 28 (USP28) and tripartite motif-containing 37 (TRIM37), in order to suppress pathways typically activated by centrosome loss. This screening identified 30 genes involved in halting the proliferation of hTERT RPE-1 cells with excess centrosomes (supetnumerary centrosomes), with 23 of these genes previously linked to centrosome-related functions.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.